CAVeA2T2评分对桡动脉-头静脉动静脉内瘘生存的临床预测价值
结果显示评分≥2与初级和次级通畅率下降显著相关,评分分层(0-1、2、3+)对初级和次级通畅率仍具显著性。结论认为CAVeA2T2评分是预测RC-AVF生存的简便有效工具,建议对评分≥2且晚期肾科转诊患者避免行RC-AVF。
要点
- CAVeA2T2评分≥2与RC-AVF初级和次级通畅率下降显著相关。
- 评分分层为0-1、2、3+时对初级和次级通畅率仍具统计学显著性。
- 建议对CAVeA2T2评分≥2且晚期肾科转诊患者避免行RC-AVF。
核心结论
- CAVeA2T2评分是预测RC-AVF生存的简便有效工具。
- 评分≥2与初级和次级通畅率下降显著相关。
- 建议对评分≥2且晚期肾科转诊患者避免行RC-AVF。
研究设计与样本
- 应用CAVeA2T2评分系统,测量初级、辅助初级和次级通畅率。
主要发现
- 平均年龄64.3±14.7岁,平均CAVeA2T2评分1.23±1.2。
- 中位内瘘次级通畅时间为13.7±1.6个月。
- 次级通畅率在6周、6、12、24个月分别为88.3%、66.7%、55%、31.7%。
- 评分增高(≥2)与初级通畅率生存下降相关(log-rank,χ2=16.7,dif=1,P=0.0001)。
- 评分增高(≥2)与次级通畅率生存下降相关(log-rank,χ2=5.4,dif=1,P=0.0001)。
关键数值与推荐
- CAVeA2T2评分组成:同侧中心静脉导管置入、年龄>73岁、静脉<2.2 mm、下肢血管成形术、术中无震颤。
- 评分分层(0-1、2、3+)对初级通畅率生存具显著性(log-rank,χ2=19.4,dif=2,P=0.0001)。
- 评分分层(0-1、2、3+)对次级通畅率生存具显著性(log-rank,χ2=5.5,dif=2,P=0.046)。
临床怎么用
- 应用CAVeA2T2评分评估RC-AVF患者,评分≥2且晚期肾科转诊者建议避免行RC-AVF。
- CAVeA2T2评分简便易用,可辅助血管通路管理决策。
局限性
- 需前瞻性研究确立高CAVeA2T2评分患者的管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiocephalic arteriovenous fistula (RC-AVF) is the recommended first choice for vascular access (VA). The CAVeA2T2 scoring system was recently published (ipsilateral central venous catheter access, age >73 years, vein <2.2 mm, lower limb angioplasty, and absent intraoperative thrill). The aim of the present study was to assess the clinical utility of the CAVeA2T2 scoring system for predicting RC-AVFs survival in our center and its subsequent application in VA management. MATERIAL AND METHODS: In this single-center retrospective study, all RC-AVFs performed from January 2010 to July 2014 were included. The CAVeA2T2 was applied. Primary, assisted primary, and secondary patency rates were measured. RESULTS: Sixty RC-AVFs were analyzed. Mean age was 64.3 ± 14.7 years. Mean CAVeA2T2 score was 1.23 ± 1.2. The median fistula secondary patency was 13.7 ± 1.6 months. Secondary patency was at 6 weeks and at 6, 12, and 24 months: 88.3%, 66.7%, 55%, and 31.7%, respectively. Increasing score (≥2) was associated with a decrease in primary (log-rank, χ2 = 16.7, dif = 1, P = 0.0001) and secondary patency rate survival (log-rank, χ2 = 5.4, dif = 1, P = 0.0001). In addition, stratification of the CAVeA2T2 score into 3 groups (scores 0-1, 2, and 3+) retained its significance for primary (log-rank, χ2 = 19.4, dif = 2, P = 0.0001) and secondary patency rate survival (log-rank, χ2 = 5.5, dif = 2, P = 0.046) at the end of the study. CONCLUSIONS: In the present study, the CAVeA2T2 scoring system has proved to be a useful, easy to apply tool that is highly predictive of RC-AVF survival. Based on our results, we should avoid perform RC-AVFs, in those patients with CAVeA2T2 score ≥2 and late nephrology referral. Prospective studies should be designed to establish the management of patients with a higher CAVeA2T2 score.
引用
- Martinez LI, Esteve V, Yeste M, et al. Clinical Utility of a New Predicting Score for Radiocephalic Arteriovenous Fistula Survival. Ann Vasc Surg. 2017. PMID: 28238926. doi:10.1016/j.avsg.2016.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。